Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evaxion Biotech ( (EVAX) ) has issued an update.
On November 6, 2025, Evaxion A/S announced significant business developments and financial results for the third quarter of 2025. Key highlights include the appointment of Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, and the presentation of promising phase 2 trial data for their personalized cancer vaccine, EVX-01, at the ESMO Congress. The company also reported the out-licensing of their bacterial vaccine candidate, EVX-B3, to MSD, which has extended their cash runway to the second half of 2027. These developments underscore Evaxion’s strategic focus on leveraging its AI-Immunology™ platform for vaccine innovation and expanding its market presence through strategic partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive developments from the earnings call, including R&D progress and financial stability. However, financial performance remains a concern due to ongoing losses and reliance on debt, impacting the valuation negatively.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating innovative vaccines for cancer and infectious diseases, leveraging artificial intelligence to enhance vaccine design and target discovery.
Average Trading Volume: 1,591,013
Technical Sentiment Signal: Sell
Current Market Cap: $35.37M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.